依达拉奉对伴胰岛素抵抗急性脑梗死患者细胞因子的影响

目的观察依达拉奉对急性脑梗死合并胰岛素抵抗患者肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)水平的影响。方法选择住院治疗急性脑梗死合并胰岛素抵抗患者90例,随机分为两组,每组45例,对照组采用常规治疗,观察组在对照组治疗的基础上加用依达拉奉治疗,同时选10例健康人做健康对照,连续监测血清中TNF-α、IL-6的动态变化;并于治疗后第7、14d进行临床疗效评定。结果两组患者治疗前TNF-α、IL-6水平均高于健康对照组(P0.05)。观察组患者治疗后第5d TNF-α、IL-6水平恢复至健康对照组水平,对照组患者在治疗后第7d时,TNF-α及IL-6水平均高于观察组患者及健康对照者(P0.05)。与对照组比较,观察组治疗后第7d、第14d BI评分明显升高、治疗后第14d SSS评分明显降低(P均0.05);观察组治疗后第14d FINS、HOMA-IR明显改善(P0.05)。结论急性脑梗死患者合并胰岛素抵抗患者予依达拉奉治疗可降低血清中TNF-α、IL-6水平,降低胰岛素抵抗,改善患者预后。

Effect of edaravone on inflammatory cytokines in serum of acute cerebral infarction patients with insulin resistance

Objective To investigate the effect of edaravone on inflammatory eytokines in serum of acute cerebral infarction patient with insulin resistances. Methods Ninety acute cerebral infarction patients were randomly divided into observation group and control group. The patients in control group were given routine treatment and the patients in observation group were given edaravone besides routine therapy. Ten serum samples from healthy persons were taken as healthy control. The levels of TNF-α, IL-6 were determined continuously and the clinical efficacy in both groups were evaluated on the 7th and 14th day after treatment. Results The levels of TNF-α and IL-6 in the patients of both groups before the treatment were significantly higher that of the healthy controls （P〈0.05）. The levels of TNF-α and IL-6 in patients of observation group drooped to the level of the healthy controls on the 5d after treatment. The levels of TNF-α and IL-6 in patients of the control group were higher than those in the observation group and the healthy control（P〈0.05 ）.Compared with the control group, the BI scores in the observation group were increased greatly on the 7th day and 14th day after treatment. And the SSS scores decreased on 14th day （P〈0.05）.Conclusions Edaravone can erduce the levels of TNF-a and IL-6 as well as low insulin resistance and improve the prognosis, Thus it is effective for treatment of patients with acute cerebral infarction.